Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPW0UL)

Drug Name

SYN-120 Drug Info

Indication

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting 5-HT 6 receptor (HTR6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LU AE58054	DMWGRQD	Schizophrenia	6A20	Phase 3	[4]
SB-742457	DM6L4ZT	Alzheimer disease	8A20	Phase 3	[5]
AVN 211	DMVB4OS	Schizophrenia	6A20	Phase 2/3	[6]
SYN120	DMDF7XB	Parkinson disease	8A00.0	Phase 2	[7]
AVN 101	DMJFLBC	Alzheimer disease	8A20	Phase 2	[6]
PF-05212377	DMPVQYR	Alzheimer disease	8A20	Phase 2	[8]
AVN 322	DMK2LGM	Cognitive impairment	6D71	Phase 2	[5]
SAM-531	DMHVJZ6	Alzheimer disease	8A20	Phase 2	[9]
SUVN-502	DMQD753	Alzheimer disease	8A20	Phase 2	[10]
BVT-74316	DMEP321	Obesity	5B81	Phase 1	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT02258152) SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
4	Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
5	5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
6	Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
7	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
8	PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
9	Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
10	Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
11	Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009 January 1; 587(Pt 1): 49-60.